- PM Modi visit USAOnly the mirror in my washroom and phone gallery see the crazy me : Sara KhanKarnataka rain fury: Photos of flooded streets, uprooted treesCannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfitRanbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A KissOscars 2022: Every Academy Award WinnerShane Warne (1969-2022): Australian cricket legend's life in picturesPhotos: What Russia's invasion of Ukraine looks like on the groundLata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)
Hockey India on Monday announced the 20-member squad for the Men's Junior Asia Cup, a qual
- Harmanpreet Singh named FIH Player of the Year, PR Sreejesh gets best goalkeeper award
- World Boxing medallist Gaurav Bidhuri to flag off 'Delhi Against Drugs' movement on Nov 17
- U23 World Wrestling Championship: Chirag Chikkara wins gold as India end campaign with nine medals
- FIFA president Infantino confirms at least 9 African teams for the 2026 World Cup
- Hockey, cricket, wrestling, badminton, squash axed from 2026 CWG in Glasgow
'BGR-34 most cost-effective Ayurvedic medicine for diabetes' Last Updated : 22 Mar 2017 04:42:59 PM IST (File photo)
More than a year after its launch, BGR-34 remains the most cost-effective Ayurvedic medicine for diabetes, claims a top executive of AIMIL Pharmaceuticals, which manufactures and markets the medicine.
"BGR-34 is a natural DPP-4 (dipeptidyl peptidase 4) inhibitor with no side effects. It is the most cost-effective Ayurvedic medicine for diabetes available at Rs 5 per tablet for patients," said K.K. Sharma, Managing Director, AIMIL.
DPP-4 inhibitors are a class of drugs used to lower blood sugar in adults with Type-2 diabetes.
The anti-diabetic herbal composition for Type-2 diabetes mellitus (NBRMAP-DB), which is sold under the trade name BGR-34, was developed by India's Council of Scientific and Industrial Research (CSIR).
The knowhow was transferred to AIMIL Pharmaceuticals for the manufacture and sale of the medicine.
The medicine is known to contribute to the maintainence of normal blood glucose metabolism, restore quality of life and reduce the chances of long-term complications.
Clinical trials of the medicine conducted have found it to be effective for Type-2 diabetes mellitus, said AIMIL Pharmaceuticals, which launched NBRMAP-DB as "BGR-34" in the market in October 2015.IANS For Latest Updates Please-
Join us on
Follow us on
172.31.16.186